Practice Updates in Genitourinary Molecular Oncology: A Case Based Approach


In line with all areas of molecular oncology, molecular testing has also expanded into the area of genitourinary tumors, providing insight into pathobiology of these tumors as well as significantly aiding in identifying diagnostic, prognostic and predictive biomarkers. Most recent guidelines from professional societies now include recommendations for relevant molecular testing in genitourinary tumors to complement the clinical practice. In this presentation, a case-based format is used to exemplify relevant established and emerging standard of care molecular biomarkers in genitourinary tumors and how pathologists can use available data from molecular pathology reports to help in their practice. The presentation will also provide guidance in selecting appropriate testing methodologies for the required assays.

Originally published on November 7, 2022

Lecture Presenter

Deepika Sirohi, MD

Deepika Sirohi, MD

Associate Professor of Pathology
University of Utah School of Medicine
Medical Director, Molecular Oncology
ARUP Laboratories

Dr. Deepika Sirohi is a medical director of molecular oncology at ARUP Laboratories and an associate professor at the University of Utah School of Medicine. Dr. Sirohi received her medical degree from the Armed Forces Medical College and then completed a residency in anatomic and clinical pathology at the University of Texas Health Science Center. She completed a genitourinary pathology fellowship at the Cedar-Sinai Medical Center and a molecular genetic pathology fellowship at the University of California. Dr. Sirohi is board certified in anatomic and clinical pathology and molecular genetic pathology. Her research interests include genomic alteration in urologic malignancies, viral oncogenesis, and applications of next generation sequencing to solid tumors.


After this presentation, participants will be able to:

  • Outline the standard of care molecular testing practices in genitourinary tumors
  • Explain molecular alterations seen in genitourinary tumors
  • Discuss, using case scenarios, how pathologists can use molecular testing for the purpose of diagnosis, suggest hereditary predisposition and testing, and integrate information from molecular tests to pathology reports

Sponsored by:

University of Utah School of Medicine, Department of Pathology, and ARUP Laboratories